Neuromodulation has the capacity to address acute and chronic effects of COVID-19

The ICNC was established in early 2020 in response to the SARS-CoV-2 pandemic, and the realization that many critically ill patients suffering from COVID-19, the disease caused by the novel coronavirus, were experiencing systemic hyperinflammation, organ failure, shock, and death.

ICNC Industry Partners

Cala Health
Cala Health
press to zoom
electroCore
electroCore
press to zoom
Neuronoff
Neuronoff
press to zoom
Soterix Medical
Soterix Medical
press to zoom
Spark Biomedical
Spark Biomedical
press to zoom